We're the first mate. The second is also being run by City of Hope, but with different exclusion criterion and aims. They use CAR-T armed with Interleukin 13 R alpha2, whilst we've got the CLTX target receptor which is what makes CHM's IP so exciting.., In that clinical trial you've outlined, they are co-using the therapy with Opdivo and Yervoy biologics.
CAR-T, the therapy time as a whole is short for Chimeric Antigen Receptor-Therapy used to describe the process of arming T-cells with specific receptor types. Chlorotoxin (CLTX) relates to our receptor ligand target.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $11.33K | 3.775M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 75 | 71644408 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 87927011 | 26 |
View Market Depth
| Last trade - 14.48pm 31/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |